ArticleInternational journal of clinical and experimental pathology2015
Influence of protein kinase C (PKC) on the prognosis of diabetic nephropathy patients.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- A Novel Approach Based on Metabolomics Coupled With Intestinal Flora Analysis and Network Pharmacology to Explain the Mechanisms of Action of Bekhogainsam Decoction in the Improvement of Symptoms of Streptozotocin-Induced Diabetic Nephropathy in Mice.Frontiers in pharmacology · 2020Article
- Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease.Journal of diabetes research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo investigate the association between protein kinase C (PKC) and the prognosis of patients with diabetic nephropathy (DN).
methods92 patients with DN who had received treatments with angiotensin converting enzyme inhibitor (ACEI) or angiotensin-receptor blockade (ARB) were collected. The clinicopathologic characteristics were recorded and a 4-year follow-up with the final result of impaired renal functions (eGFR < 40 mL/min) was conducted. The expression of PKC was detected by immunohistochemical assay. Kaplan-Meier and Cox regression analysis were performed to estimate the effects of PKC on DN prognosis.
resultsAccording to immunohistochemical analysis, there were 54 cases with positive expression of PKC (positive rate 58.7%). Meanwhile, during the follow-up, the urine protein, mean serum creatinine and eGFR in patients with positive PKC were all higher than those in negative expression group (P < 0.05). The expression of PKC was influenced by age (P < 0.001), course of disease (P < 0.001), blood pressure (P = 0.002), blood glucose (P < 0.001), HbA1c (P = 0.002), renal functions of patients before (P = 0.011) and after (P = 0.041) the biopsy. Besides, the Kaplan-Meier curve revealed that patients with positive PKC expression had shorter survival time than those with negative PKC expression (P < 0.001). Cox regression analysis indicated that HbA1c (P = 0.009), renal functions of patients after the biopsy (P = 0.002) and PKC (P = 0.028) were important factors in the prognosis of DN and they might be independent prognostic markers.
conclusionThe expression of PKC is relatively higher in DN patients than in healthy controls. And PKC may be a valuable prognostic marker for patients with DN.
Indexed as
Identifiers
26823823PMC4713609W2408776650What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.